Clinical Trials Logo

Osteoporosis clinical trials

View clinical trials related to Osteoporosis.

Filter by:

NCT ID: NCT00545116 Completed - Osteoporosis Clinical Trials

Effects of Hesperidin on Bone Biomarkers in Postmenopausal Women

Start date: October 2007
Phase: Phase 2
Study type: Interventional

The primary objective of this clinical trial is to determine the effects of hesperidin on biochemical markers of bone in post-menopausal women. The secondary objectives are: - To investigate changes in bone formation and bone resorption markers in response to hesperidin intake - To compare the efficacy of hesperidin in a milk versus biscuit - To collect safety information of hesperidin consumption in a human trial

NCT ID: NCT00545090 Completed - Clinical trials for Post Menopausal Osteoporosis

ExBonAdAsia Study: A Study of Once Monthly Bonviva (Ibandronate) in Women With Post-Menopausal Osteoporosis.

Start date: August 2006
Phase: Phase 4
Study type: Interventional

This single arm study will continue drug safety surveillance, and assessment of adherence, in patients with postmenopausal osteoporosis who have received monthly oral Bonviva in ML19930, the BonAdAsia study. All patients completing 6 months in ML19930 will continue to receive Bonviva (150mg po, monthly) for an additional 6 months. The anticipated time on study treatment is 3-12 months, and the target sample size is 500+ individuals.

NCT ID: NCT00545051 Completed - Clinical trials for Postmenopausal Osteoporosis

A Study of Once Monthly Bonviva (Ibandronate) in Prevention of Glucocorticoid-Induced Osteoporosis.

Start date: May 2006
Phase: Phase 4
Study type: Interventional

This 2 arm study will investigate the efficacy and safety of Bonviva (150mg po monthly) in the prevention of glucocorticoid-induced osteoporosis in post-menopausal women. Patients will be randomized to receive either Bonviva 150mg po or placebo monthly, with vitamin D and calcium supplementation. The anticipated time on study treatment is 1-2 years, and the target sample size is 100-500 individuals.

NCT ID: NCT00544180 Terminated - Osteoporosis Clinical Trials

ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a Week

Start date: May 2005
Phase: Phase 4
Study type: Interventional

To determine the satisfaction of subject with Actonel 35 mg Once a Week in the treatment of post-menopausal osteoporosis. Open, non-controlled, multi-center study.

NCT ID: NCT00543218 Completed - Clinical trials for Osteoporosis, Post-Menopausal

PTH Comparison in Post Menopausal Women

Start date: December 2002
Phase: Phase 3
Study type: Interventional

Compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD.

NCT ID: NCT00543023 Completed - Clinical trials for Osteoporosis, Post-Menopausal

A Study of the Treatment of Postmenopausal Women With Osteoporosis

Start date: June 2003
Phase: Phase 3
Study type: Interventional

To compare the effect of treatment with teriparatide with that of salmon calcitonin in postmenopausal women with osteoporosis.

NCT ID: NCT00542984 Completed - Clinical trials for Osteoporosis, Postmenopausal

Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis

Start date: August 2003
Phase: Phase 3
Study type: Interventional

To compare in postmenopausal women with established osteoporosis the effect of treatment with teriparatide 20 micrograms/day subcutaneous with the effect of salmon calcitonin 100 IU/day subcutaneous on change in lumbar spine BMD.

NCT ID: NCT00542425 Completed - Osteoporosis Clinical Trials

Phase 2 Dose-finding Study to Evaluate the Effects of BA058 in the Treatment of Postmenopausal Women With Osteoporosis

Start date: April 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether BA058 is effective in building bone in postmenopausal women with osteoporosis.

NCT ID: NCT00541658 Completed - Clinical trials for Postmenopausal Osteoporosis

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

Start date: October 2007
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to study the efficacy of a 35 mg delayed release weekly dosing regimen as compared to the standard daily dosing regimen of risedronate 5 mg daily.

NCT ID: NCT00540878 Completed - Osteoporosis Clinical Trials

A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy Women

Start date: April 2007
Phase: Phase 1
Study type: Interventional

This study will examine the effects of formulation on the relative bioavailability of SB-751689 (400 mg) administered to healthy postmenopausal women. Subjects will receive a single oral dose of each formulation, with five formulations of SB-751689 tested in total. Blood samples will be taken up to 24 hours postdose after each dose administration. This study will provide information for future possible formulation development of SB-751689 for Phase III.